Acción INIT INITIATOR PHARMA A/S
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Initiator Pharma A/S

Acciones

INIT

DK0060775872

Mercado cerrado - Nasdaq Stockholm
Otros sitios de cotización
 17:29:59 26/04/2024 		Varia. Cinco días. Varia. 1 de enero.
8,78 SEK -1,79 % Gráfico intradía de Initiator Pharma A/S -2,23 % -4,98 %
23/02 Initiator Pharma A/S informa de los resultados del cuarto trimestre y del año completo finalizado el 31 de diciembre de 2023 CI
21/02 Initiator Pharma emite nuevas acciones para la conversión de deuda MT

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Initiator Pharma's pudafensine preclinical pharmacology results published in the British Journal of Pharmacology
Initiator Pharma’s pudafensine preclinical pharmacology results published in the British Journal of Pharmacology
Initiator Pharma - Q4 2023 – Breathing optimism
INITIATOR PHARMA: YEAR END REPORT 2023
Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Initiator Pharma Issues New Shares for Debt Conversion
MAC Clinical Research converts its receivable into shares in Initiator Pharma
Initiator Pharma A/S - Issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021
Issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021
Initiator Pharma expands its position to a broader Sexual Health Franchise and intensifies its business development efforts
Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts
Initiator Pharma Q3 - A historical quarter
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Initiator Pharma reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensine
Initiator Pharma - Positive Phase IIb results
Initiator Pharma reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensine
Initiator Pharma reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensine
Initiator Pharma A/S Announces Positive Results from Phase IIb Clinical Trial with Pudafensine
Result of incentive program LTI2023 in Initiator Pharma
Initiator Pharma announces indication expansion, clinical drug candidates active in models of female sexual dysfunction
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción INIT
  4. Noticias Initiator Pharma A/S
  5. Otros idiomas